Name | Title | Contact Details |
---|
Ritter Pharmaceuticals, Inc. is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem (digestive tract). Ritter Pharmaceuticals, Inc. is rapidly establishing itself as the world`s leader in lactose intolerance research based upon its scientific team and their cutting edge research in this field. RP-G28, Ritter`s lead product, has been studied in a Phase 2 trial and is a first-in-class compound. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease which affects over 1 billion people worldwide.
Angels of Flight Canada Inc. is a Peterborough, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Eclipse Systems Inc is a Branford, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Call9 is a technology company innovating medical services and systems in EmergencyMedicine and PalliativeCare.
RegenScientific, a wholly-owned business unit of Cytophil, Inc., an ISO 13485 certified company, is dedicated to providing physicians and patients with high-quality, safe, efficacious, and cost-effective soft tissue augmentation implants. The company has CE-Mark for its Renú® Soft Tissue (Volumizing) Implant for lipoatrophy, vocal fold insufficiency, and soft tissue augmentation in Europe. The Company has FDA 510k clearances for its Renú® Gel and Renú® Voice otolaryngology products indicated for vocal fold injection augmentation. Renú® is a registered trademark of Cytophil, Inc. REGENSCIENTIFIC™ and the REGENSCIENTIFIC logo are trademarks of Cytophil, Inc.